Pretransplantation adaptation of the daily dose of tacrolimus to CYP3A5 genotype is
associated with improved achievement of target trough concentration (C 0), but whether this …

Retrospective studies have demonstrated that patients who are expressors of cytochrome
P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a therapeutic trough …

Previously, we reported that, at 3 months after renal transplantation, individuals with
CYP3AP1 genotype CYP3AP1* 1 (linked to CYP3A5* 1 and strongly associated with …

Aims Although cytochromeP450 (CYP) 3A5 gene polymorphism affects personalized
tacrolimus doses, there is no consensus as to whether CYP3A5 genotypes should be …

Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …

Kidney transplant recipients carrying the CYP3A5* 1 allele have lower tacrolimus troughs,
and higher dose requirements compared to those with the CYP3A5* 3/* 3 genotype …

The calcineurin inhibitor tacrolimus is the backbone of immunosuppressive drug therapy
after solid organ transplantation. Tacrolimus is effective in preventing acute rejection but has …

Objectives We investigated the pharmacokinetic and pharmacogenetic implications of
conversion from a twice-daily (P-Tac) to a once-daily (A-Tac) tacrolimus (Tac) formulation …

Purpose The purpose of this study is to determine the impacts of CYP3A5 polymorphism on
tacrolimus concentration and the proportion of patients within a target therapeutic range …

Tacrolimus, widely used to prevent acute rejection following solid‐organ transplantation, has
become the cornerstone of immunosuppressive therapy after kidney transplantation. More …